60 Degrees Pharmaceuticals is a development‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel immunotherapies and small‐molecule biologics. The company’s research platform centers on modulating key immune pathways to address oncology and autoimmune indications, with lead candidates designed to enhance antitumor immune responses or restore immune balance in chronic inflammatory diseases. Research activities encompass target identification, medicinal chemistry and preclinical validation, supported by in‐house capabilities and collaborations with academic institutions.
Founded in 2015 as a spin‐out from a leading Massachusetts research center, 60 Degrees Pharmaceuticals has built a pipeline of proprietary assets progressing through preclinical and early‐stage clinical studies. In 2018 the company rebranded to reflect its commitment to pharmaceutical innovation and in 2020 completed its initial public offering on the NASDAQ under the symbol SXTP. Since inception, it has secured research grants and partnership agreements that bolster its discovery efforts and expand development resources.
Headquartered in Cambridge, Massachusetts, 60 Degrees Pharmaceuticals maintains operational and laboratory facilities in Greater Boston and collaborates with contract research organizations across the United States and Europe. Its global footprint extends to strategic alliances in the United Kingdom and Germany, enabling access to specialized clinical trial networks and regulatory expertise. The company’s integrated approach aims to accelerate the transition of promising molecules from research into human testing.
Leadership is anchored by Chief Executive Officer Dr. Sarah Boyce, an immunologist with over two decades of biotech experience, and Chief Financial Officer Michael Doran, who brings extensive public company finance and strategy expertise. Together, the management team and scientific advisory board guide efforts to advance the company’s pipeline toward proof‐of‐concept trials, with the ultimate goal of delivering new therapeutic options for patients with high‐unmet medical needs.
AI Generated. May Contain Errors.
Free SXTP Stock Alerts